Bordetella bronchiseptica is primarily an animal pathogen, best known for causing kennel cough in dogs and snuffles in rabbits, but it can jump to humans and occasionally cause serious respiratory disease. Human infections are uncommon, and most reported cases involve people whose immune systems are compromised by HIV/AIDS, organ transplants, cancer treatment, or advanced age. The bacterium’s ability to persist inside immune cells, form protective biofilms, and toggle its virulence genes on and off makes it a more formidable pathogen than its reputation as “just an animal bug” suggests.
An Ancestor of Whooping Cough
B. bronchiseptica belongs to a small group of closely related Bordetella species that include B. pertussis, the cause of whooping cough, and B. parapertussis, which causes a milder pertussis-like illness. Genomic comparisons have shown that B. pertussis and B. parapertussis each evolved independently from B. bronchiseptica-like ancestors. During that evolution, the human-adapted species lost large chunks of their genomes rather than gaining new capabilities. Differences in how severely each species causes disease appear to stem from lost regulatory controls rather than newly acquired weapons.1Nature Genetics. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica
The genus itself traces back even further than animals. Phylogenetic studies have recovered Bordetella sequences from environmental soil and water samples and found that these environmental strains sit closer to the root of the evolutionary tree, with significantly higher genetic diversity than the animal-associated species. B. bronchiseptica and B. hinzii have even retained the ability to grow in soil, a vestige of their environmental ancestry.2PubMed Central. Environmental Origin of the Genus Bordetella This matters because it means B. bronchiseptica is a generalist: comfortable in the environment, comfortable in dozens of animal species, and occasionally comfortable enough in a human host to cause real trouble.
How the Bacterium Causes Disease
At the center of B. bronchiseptica’s pathogenic toolkit is a master regulatory switch called the BvgAS system. This two-component system acts as a sensor: the BvgS protein detects environmental signals, and through a chain of chemical relays, it activates BvgA, which then turns on the genes the bacterium needs for infection. These include genes for toxins and adhesins, the molecules that let the bacterium stick to respiratory tissue.3PubMed Central. Lonidamine, a Novel Modulator for the BvgAS System of Bordetella Species The system also represses a separate set of genes that are active only when the bacterium is in its non-virulent phase, suggesting the organism cycles between states depending on whether it is actively infecting a host or surviving in the environment.4PubMed. Identification and genomic organization of gene loci negatively controlled by the virulence regulatory BvgAS two-component system in Bordetella bronchiseptica BvgAS kinase activity is essential for respiratory infection: without it, the bacterium cannot establish itself in the airways.5PubMed Central. The BvgS PAS Domain, an Independent Sensory Perception Module in the Bordetella bronchiseptica BvgAS Phosphorelay
One interesting difference between B. bronchiseptica and its more famous relative B. pertussis concerns pertussis toxin. B. pertussis produces this toxin in large amounts, and it is a major driver of whooping cough severity. B. bronchiseptica carries the complete genetic blueprint for pertussis toxin, but mutations in the promoter region have silenced it. The toxin gene is there; it just doesn’t get read.6PubMed Central. Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations Similarly, the adenylate cyclase toxin, a virulence factor shared across the pathogenic Bordetella species, works differently in B. bronchiseptica. A host protein called 14-3-3 can inactivate the B. bronchiseptica version of this toxin but not the B. pertussis version, which partly explains why B. pertussis is so much more damaging to epithelial barriers in the human airway.7PubMed Central. The Eukaryotic Host Factor 14-3-3 Inactivates Adenylate Cyclase Toxins of Bordetella bronchiseptica and B. parapertussis, but Not B. pertussis
Iron availability adds another layer. When the bacterium senses that iron is scarce, as it often is inside a host, it ramps up its type III secretion system. This molecular syringe injects toxic proteins directly into host cells. Under iron-starved conditions, the resulting cell damage and red blood cell lysis are greatly enhanced.8PubMed. Iron starvation regulates the type III secretion system in Bordetella bronchiseptica
Surviving Inside the Body’s Own Defenses
One of the more surprising aspects of B. bronchiseptica biology is its ability to live inside the very cells meant to destroy it. When macrophages (the immune system’s front-line scavenger cells) engulf B. bronchiseptica, the bacteria end up in an acidic compartment that would kill most other microbes. B. pertussis dies quickly at pH 4.5 to 5.0, but B. bronchiseptica tolerates these conditions and can persist inside macrophages for days. Experiments that artificially raised the pH inside infected macrophages produced a counterintuitive result: B. pertussis survived better in the less acidic environment, while B. bronchiseptica actually survived worse. The bacterium seems to have adapted to thrive under exactly the hostile conditions the immune system creates.9PubMed. Phagosome acidification has opposite effects on intracellular survival of Bordetella pertussis and B. bronchiseptica
This intracellular persistence is compounded by biofilm formation. B. bronchiseptica can build structured communities on respiratory surfaces, encased in a self-produced matrix. A key component is a polysaccharide produced by the bpsABCD gene cluster. Studies in swine have demonstrated that this polysaccharide is required for the three-dimensional biofilm architecture the bacterium forms under flow conditions, and that biofilm formation enhances survival in the lower respiratory tract.10PubMed Central. The Bordetella Bps Polysaccharide Is Required for Biofilm Formation and Enhances Survival in the Lower Respiratory Tract of Swine Biofilms shield bacteria from both the immune system and antibiotics, and this lifestyle has been proposed as the mechanism behind the chronic, hard-to-clear respiratory infections that B. bronchiseptica is known for in animals and occasionally in humans.11PubMed Central. Bordetella biofilms: a lifestyle leading to persistent infections
How Humans Get Infected
B. bronchiseptica circulates widely among domestic and wild animals. Dogs and cats are probably the most common source of human exposure, and the bacterium can be found in the nose and throat of these animals even when they appear healthy.12PubMed Central. Identification of Bordetella bronchiseptica in the throat and nose of dogs and cats by PCR In published case reports, the link to a specific animal is often clear. A 75-year-old woman who developed necrotizing cavitary pneumonia had close daily contact with a coughing pet cat, which was identified as the likely source.13International Journal of Case Reports and Images. Necrotizing and cavitary pneumonia due to Bordetella bronchiseptica transmission from a cat: A case report Another case involved an immunocompetent 74-year-old man whose chronic respiratory symptoms, including productive cough and significant weight loss lasting three years, were traced back to contact with a dog.14American Journal of Respiratory and Critical Care Medicine. C69-02 Delayed Dog-Associated Bordetella Bronchiseptica Bronchopneumonia in an Immunocompetent Host: An Unusual Report
Transmission doesn’t require a visibly sick animal. One documented case involved zoonotic transmission of a vaccine-derived strain: a 43-year-old immunocompromised woman developed a B. bronchiseptica infection after her dog received a live attenuated intranasal Bordetella vaccine. The bacterium recovered from the patient matched the vaccine strain.15PubMed Central. Zoonotic Transmission of Vaccine-Derived Bordetella bronchiseptica This is a scenario pet owners and their physicians rarely think about, but it highlights that even routine veterinary care can create a brief window of risk for someone with a weakened immune system living in the same household.
Who Is Most at Risk
The population at greatest risk is people with compromised immune function. A case series and literature review found that B. bronchiseptica rarely causes serious infection in people with healthy immune systems. But in patients who are immunosuppressed, particularly those undergoing stem cell transplants, solid organ transplants, or treatment for malignancies, the bacterium can cause severe pulmonary disease.16PubMed Central. Bordetella bronchiseptica in the immunosuppressed population – a case series and review Among HIV-infected patients, a study identified nine people with culture-confirmed infections. All nine had experienced at least one AIDS-defining condition before their B. bronchiseptica infection, and the infections ranged from mild upper respiratory illness to full pneumonia, with one disseminated case.17Clinical Infectious Diseases. Bordetella bronchiseptica Infection in Human Immunodeficiency Virus-Infected Patients
Older adults, even without a clear immunodeficiency, also appear vulnerable. The cases of a 75-year-old woman with cavitary pneumonia and a 74-year-old man with years of chronic respiratory symptoms show that age and the presence of other medical conditions can tip the balance, allowing what would normally be a self-limiting exposure to become a prolonged or destructive infection.
Clinical Presentation
The spectrum of illness is wide. At the mild end, patients may experience a persistent cough, sometimes with sputum production, resembling a stubborn bronchitis. At the severe end, the infection can progress to full pneumonia, including necrotizing and cavitary forms where lung tissue is destroyed and holes form in the lung parenchyma. Symptoms typically include fever, shortness of breath, productive cough, and sometimes pleuritic chest pain. Weight loss and prolonged illness lasting months or years have been reported in cases where the diagnosis was delayed.
Co-infection with other respiratory pathogens can worsen outcomes. In veterinary models, pigs simultaneously infected with a respiratory coronavirus and B. bronchiseptica developed more severe lung damage and a more intense inflammatory response, driven by elevated levels of inflammatory signaling molecules, than animals infected with either pathogen alone.18PubMed Central. Coinfection of pigs with porcine respiratory coronavirus and Bordetella bronchiseptica This synergistic effect has clinical relevance for humans. A renal transplant patient who developed COVID-19 pneumonia subsequently developed a B. bronchiseptica superinfection, suggesting that viral respiratory illness can create an opening for this opportunistic bacterium.19PubMed Central. Coinfection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Bordetella bronchiseptica Pneumonia in a Renal Transplant Patient Among dogs, co-infections involving B. bronchiseptica and other respiratory viruses are extremely common, detected in nearly half of B. bronchiseptica-positive animals in one study.20PubMed Central. Detection of respiratory viruses and Bordetella bronchiseptica in dogs with acute respiratory tract infections
Diagnosis
Identifying B. bronchiseptica in a human clinical specimen requires some effort because laboratories may not be expecting it. The bacterium grows on standard culture media but can be slow, and clinicians may not specifically request it if they do not suspect an unusual organism. Culture remains the gold standard for confirmation, and once colonies grow, mass spectrometry has become a reliable tool for rapid identification. A study validating the use of MALDI-TOF MS for Bordetella species confirmed all tested isolates at the genus level and identified over 93% correctly at the species level.21PubMed Central. Automatic Identification of MALDI-TOF MS Database Using Classical Bordetella Species Isolates A sensitive culture method followed by MALDI-TOF MS screening has also been developed specifically to detect B. bronchiseptica and other unusual Bordetella species in clinical samples from patients with pertussis-like symptoms.22PubMed. Prevalence of Bordetella holmesii and Bordetella bronchiseptica in respiratory tract samples from Belgian patients with pertussis-like symptoms by sensitive culture method and mass spectrometry
A key practical point: because human B. bronchiseptica infection is rare, it can easily be missed if the laboratory is only looking for common respiratory bacteria. A prolonged cough in someone with animal exposure and immune compromise should prompt specific consideration. Informing the microbiology lab that an unusual Bordetella species is a possibility can help ensure the organism is not dismissed as a contaminant.
Antibiotic Resistance Patterns
B. bronchiseptica’s susceptibility to antibiotics does not follow the same rules as B. pertussis. Resistance patterns have been characterized primarily from veterinary isolates, but these data inform treatment choices in human infections. A review of antimicrobial resistance found that B. bronchiseptica typically shows low minimum inhibitory concentrations for most drug classes but has naturally elevated resistance to beta-lactam antibiotics and macrolides.23PubMed Central. Antimicrobial Resistance in Bordetella bronchiseptica This is a critical distinction: macrolides like azithromycin are the first-line treatment for B. pertussis whooping cough, so a clinician who assumes B. bronchiseptica should be treated the same way may choose a drug that doesn’t work well.
A study of 78 canine isolates found universal susceptibility to tetracycline, doxycycline, enrofloxacin, and amoxicillin-clavulanate. Susceptibility to plain ampicillin was about 81%, and to trimethoprim about 73%.24PubMed. Antibiotic susceptibility of canine Bordetella bronchiseptica isolates On the molecular side, a handful of resistance genes have been identified in resistant isolates, including tetracycline resistance genes and genes conferring resistance to chloramphenicol and related drugs.23PubMed Central. Antimicrobial Resistance in Bordetella bronchiseptica The genetic basis of resistance remains poorly characterized overall, but the existence of transferable resistance genes suggests the potential for resistance to spread, particularly in settings where animals receive frequent antibiotic treatment.
Treatment
There are no randomized controlled trials guiding B. bronchiseptica treatment in humans; clinicians rely on case reports, susceptibility testing, and extrapolation from veterinary data. Based on the resistance profile described above, fluoroquinolones, tetracyclines, and trimethoprim-sulfamethoxazole are commonly used. Amoxicillin-clavulanate is another option given the consistent in-vitro activity. Standard ampicillin or amoxicillin alone may be less reliable because of variable susceptibility.
Published case reports describe successful outcomes with appropriate antibiotic selection. A patient with lung cancer who developed B. bronchiseptica pneumonia was managed with targeted antibiotic therapy and recovered.25PubMed Central. Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection The renal transplant patient co-infected with SARS-CoV-2 showed rapid clinical and radiological improvement with azithromycin.19PubMed Central. Coinfection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Bordetella bronchiseptica Pneumonia in a Renal Transplant Patient That azithromycin worked well in the latter case, despite the organism’s general tendency toward macrolide resistance, underscores why susceptibility testing matters for every isolate. The MIC can vary from one strain to the next, and blind empiric therapy carries a real risk of failure.
Duration of treatment is not standardized. In mild cases, a typical course of one to two weeks may suffice. In patients with deep-seated infection, especially cavitary or necrotizing pneumonia, prolonged courses and close imaging follow-up are advisable. The bacterium’s biofilm-forming ability and intracellular persistence mean that short courses might suppress symptoms without fully clearing the organism, setting the stage for relapse.
Prevention and the One Health Angle
There is no human vaccine against B. bronchiseptica. Veterinary vaccines exist, both injectable killed versions and intranasal live attenuated formulations, but as the vaccine-derived transmission case illustrates, these can occasionally be part of the problem rather than the solution for vulnerable household contacts. If you are immunocompromised and a pet in your home is due for an intranasal Bordetella vaccine, it is worth discussing the timing and type of vaccine with your veterinarian and your own physician. Some experts suggest using the injectable killed vaccine instead for households with immunosuppressed members, though formal guidelines on this are limited.
At a broader level, researchers have begun framing B. bronchiseptica as a One Health challenge, one that sits at the intersection of animal health, human health, and environmental surveillance. A recent study examining the swine-to-human transmission interface proposed a surveillance approach that combines tracking of the bacterium’s genetic elements across hosts, screening for recombination hotspots that could increase virulence, and monitoring metabolic shifts that signal adaptation to human tissue.26PubMed Central. Zoonotic Bordetella bronchiseptica infection at the swine-human interface: unveiling the evolutionary path from an animal to a human pathogen The concern is not that B. bronchiseptica will suddenly become a widespread human pandemic pathogen. The concern is that ongoing, low-level exposure across millions of human-animal contacts creates opportunities for the bacterium to pick up new resistance genes or acquire mutations that make it better at infecting humans, and we currently have almost no surveillance infrastructure to detect that shift early.
When to Suspect B. bronchiseptica
For clinicians and patients alike, a few red flags should raise suspicion. A prolonged respiratory illness that does not respond to standard empiric antibiotics, particularly macrolides, in someone who lives with dogs, cats, rabbits, or pigs. Pertussis-like symptoms in a person whose pertussis testing comes back negative. A pneumonia in an immunocompromised patient with a known animal exposure history. In all of these scenarios, asking the laboratory to specifically look for B. bronchiseptica, rather than just running a standard respiratory panel, can make the difference between a delayed diagnosis and a prompt one. The organism is not difficult to treat once identified, but it is easy to miss if nobody is thinking about it.